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A standard approach to trial design is to test a null
hypothesis of no treatment effect in terms of a primary
outcome measure against an alternative hypothesis of a
minimal clinically relevant treatment effect as chosen by
the investigators. Sample size is determined to maximise
the chance that the trial detects this effect if it exists whilst
minimising the chance of a false positive conclusion. We
propose a reverse philosophy is used in rare diseases
where the design starts with the number of patients that is
feasible to collect within a sensible time frame and then,
based on a Bayesian analysis, show that this amount of
data could provide useful information on which to make
clinical decisions in the future.
This paper illustrates application of this approach to
design the first ever potentially practice-changing trial in
penile cancer, as part of the International Rare Cancers
Initiative. The primary outcome measure is survival time
with treatment effect measured as a hazard ratio. Given a
predicted number of events, the design is evaluated by (i)
demonstrating the information that the trial could provide
for a range of possible observed results and prior distribu-
tions; and (ii) given a pre-specified decision criteria, using
simulation to determine the probability that the trial will
make the correct decision under different underlying true
scenarios.
Treatment decisions in rare diseases should be based
on trial evidence but the traditional approach to design
is problematic and using a Bayesian approach with
reverse philosophy may provide a practical alternative.
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